HRP20100614T4 - Soli 3,7-diamino-10h-fenotiazina i njihova uporaba - Google Patents

Soli 3,7-diamino-10h-fenotiazina i njihova uporaba Download PDF

Info

Publication number
HRP20100614T4
HRP20100614T4 HRP20100614TT HRP20100614T HRP20100614T4 HR P20100614 T4 HRP20100614 T4 HR P20100614T4 HR P20100614T T HRP20100614T T HR P20100614TT HR P20100614 T HRP20100614 T HR P20100614T HR P20100614 T4 HRP20100614 T4 HR P20100614T4
Authority
HR
Croatia
Prior art keywords
compound
r3nb
r7nb
r7na
r3na
Prior art date
Application number
HRP20100614TT
Other languages
English (en)
Croatian (hr)
Inventor
Claude Michel Wischik
Janet Elizabeth Rickard
Charles Robert Harrington
David Horsley
John Mervyn David Storey
Colin Marshall
James Peter Sinclair
Thomas Craven Baddeley
Original Assignee
Wista Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38421429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100614(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wista Laboratories Ltd. filed Critical Wista Laboratories Ltd.
Publication of HRP20100614T1 publication Critical patent/HRP20100614T1/xx
Publication of HRP20100614T4 publication Critical patent/HRP20100614T4/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B21/00—Thiazine dyes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
HRP20100614TT 2006-03-29 2007-03-28 Soli 3,7-diamino-10h-fenotiazina i njihova uporaba HRP20100614T4 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78669006P 2006-03-29 2006-03-29
PCT/GB2007/001103 WO2007110627A2 (en) 2006-03-29 2007-03-28 3,7-diamino-10h-phenothiazine salts and their use
EP07732164.4A EP2013191B3 (en) 2006-03-29 2007-03-28 3,7-diamino-10h-phenothiazine salts and their use

Publications (2)

Publication Number Publication Date
HRP20100614T1 HRP20100614T1 (hr) 2010-12-31
HRP20100614T4 true HRP20100614T4 (hr) 2019-08-09

Family

ID=38421429

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20100614TT HRP20100614T4 (hr) 2006-03-29 2007-03-28 Soli 3,7-diamino-10h-fenotiazina i njihova uporaba

Country Status (18)

Country Link
US (5) US7888350B2 (enExample)
EP (1) EP2013191B3 (enExample)
JP (3) JP5520043B2 (enExample)
KR (1) KR100983301B1 (enExample)
CN (5) CN104119294B (enExample)
AT (1) ATE478058T3 (enExample)
AU (1) AU2007231124B2 (enExample)
CA (1) CA2646163C (enExample)
DE (1) DE602007008550D1 (enExample)
DK (1) DK2013191T6 (enExample)
EA (1) EA014552B1 (enExample)
ES (1) ES2349322T7 (enExample)
HR (1) HRP20100614T4 (enExample)
IL (2) IL194516A (enExample)
MY (1) MY143757A (enExample)
PL (1) PL2013191T6 (enExample)
PT (1) PT2013191E (enExample)
WO (1) WO2007110627A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5186212B2 (ja) 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
DK2004155T3 (en) 2006-03-29 2018-04-30 Wista Lab Ltd PROTEIN AGGREGATION INHIBITORS
MY162313A (en) 2006-07-11 2017-05-31 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
US8227459B2 (en) * 2007-04-03 2012-07-24 Prosetta Antiviral Inc. Diamino-phenothiazinyl derivatives as antiviral treatments
AU2008265045B2 (en) * 2007-06-19 2014-02-27 Taurx Therapeutics Management Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
FR2920775B1 (fr) * 2007-09-07 2009-11-06 Pharma Hydro Dev P H D Soc Par Nouveaux composes diaminophenothiazine, leur procede de preparation et leurs utilisations.
PT2954932T (pt) * 2007-10-03 2018-12-12 Wista Lab Ltd Utilização terapêutica de diaminofenotiazinas
EP3689346B1 (en) 2008-12-10 2024-01-24 WisTa Laboratories Ltd. 3,6-disubstituted xanthylium salts for treating tauopathies
WO2011036561A2 (en) * 2009-09-24 2011-03-31 Wis Ta Laboratories Ltd. Process
KR20170061177A (ko) * 2009-09-24 2017-06-02 위스타 레보레이토리스 리미티드 결정질 메틸티오니늄 클로라이드（메틸렌 블루） 수화물
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
US8785434B2 (en) 2010-04-30 2014-07-22 Prosetta Antiviral Inc. Antiviral compounds
ES2655492T3 (es) 2010-11-30 2018-02-20 Wista Laboratories Ltd. Formulaciones que comprenden cloruro de metiltioninio
WO2012106363A2 (en) 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Treatment of tauopathies
KR101888713B1 (ko) * 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
US20130315825A1 (en) * 2012-05-03 2013-11-28 Washington University Tricyclic heteroaromatic compounds as alpha-synuclein ligands
GB201512678D0 (en) 2015-07-20 2015-08-26 Wista Lab Ltd Methods of chemical synthesis
CN105541756B (zh) * 2015-12-17 2018-02-09 陕西方舟制药有限公司 一种制备1‑(3，7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法
ITUA20163526A1 (it) * 2016-05-17 2017-11-17 Icrom Spa Procedimento per la preparazione di composti diamminofenotiazinici ad elevato grado di purezza
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
GB201621817D0 (en) 2016-12-21 2017-02-01 Wista Lab Ltd Methods of chemical synthesis
CN107253936B (zh) * 2017-06-23 2021-07-23 复旦大学 一类可用于次氯酸检测的荧光探针及其制备方法和应用
CN108129418A (zh) * 2017-12-22 2018-06-08 郑州大学 吩噻嗪-氨基二硫代甲酸酯衍生物及其制备方法和应用
BR112021000802A2 (pt) 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações
CN120148902A (zh) 2018-09-05 2025-06-13 云顶道卫思诊断中心有限公司 神经系统变性疾病的网络方法
CN109223800A (zh) * 2018-10-26 2019-01-18 辽宁大学 3,7-二对甲苯胺基-吩噻嗪-5-鎓碘化物与超声协同在抑制肿瘤细胞增殖中的应用
CN113874078B (zh) 2019-04-05 2025-05-06 Tauc3生物制品有限公司 抗tauc3抗体及其应用
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
CN116056724A (zh) 2020-05-05 2023-05-02 维斯塔实验室有限公司 用于治疗covid-19的甲基硫堇鎓化合物
GB202006659D0 (en) 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
ES2992641T3 (en) 2020-05-05 2024-12-16 Wista Lab Ltd Methylthioninium compounds for use in the treatment of hypoxemia
GB202010652D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd Anti-tau antibodies
DE102020212508A1 (de) 2020-10-02 2022-04-07 Continental Reifen Deutschland Gmbh Verbindung, Kautschukmischung enthaltend die Verbindung, Fahrzeugreifen, der die Kautschukmischung in wenigstens einem Bauteil aufweist, Verfahren zur Herstellung der Verbindung sowie Verwendung der Verbindung als Alterungsschutzmittel und/oder Antioxidationsmittel und/oder Antiozonant und/oder Farbstoff
GB202204185D0 (en) 2022-03-24 2022-05-11 Wista Lab Ltd Oral treatment
CA3257856A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT)
WO2024063700A1 (en) 2022-09-21 2024-03-28 Yin Sze Loh Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases
US12410394B2 (en) 2023-01-06 2025-09-09 Athergen, Inc. Composition comprising nicotinamide mononucleotide and leucomethylene blue
KR20250154422A (ko) 2023-03-03 2025-10-28 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 미세혈관 뇌질환 치료를 위한 디아미노페노티아진
CN117447421A (zh) * 2023-10-30 2024-01-26 上海沃凯生物技术有限公司 一种3,7-双-（二甲胺基）-吩噻嗪的合成方法
GB202500018D0 (en) 2025-01-02 2025-02-19 Wista Lab Ltd Long term dosing of neurodegenerative disorders utilising methylthioninium (mt) containing compounds

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE569430A (enExample) 1957-07-17
US3641016A (en) * 1968-02-16 1972-02-08 Egyt Gyogyszervegyeszeti Gyar Thionine derivatives
JPS52105931A (en) * 1976-03-02 1977-09-06 Mita Industrial Co Ltd New leuco coloring matters and process for manufacture thereof
US4309255A (en) 1980-09-10 1982-01-05 International Business Machines Corporation Electrochromic recording paper
US4622395A (en) 1984-10-01 1986-11-11 Minnesota Mining And Manufacturing Company Phenoxazine and phenothiazine dyes and leuco forms thereof
US4647525A (en) 1984-10-01 1987-03-03 Minnesota Mining And Manufacturing Company Stabilized leuco phenazine dyes and their use in an imaging system
GB8724412D0 (en) 1987-10-19 1987-11-25 Medical Res Council Protein
US5571666A (en) 1988-10-28 1996-11-05 Oklahoma Medical Research Foundation Thiazine dyes used to inactivate HIV in biological fluids
CA2011116C (en) * 1989-03-06 1999-11-16 Murray A. Kaplan Lyophilized bmy-28142 dihydrochloride for parenteral use
US5220009A (en) * 1990-05-03 1993-06-15 Yeda Research And Development Company Limited Phenothiazinium salts and their use for disinfecting aqueous effluents
JPH0725786A (ja) 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
WO1993003369A1 (en) 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
WO1993003177A1 (en) 1991-08-09 1993-02-18 Massachusetts Institute Of Technology Novel tau/neurofilament protein kinases
DE4140192C2 (de) 1991-12-05 1996-02-29 Alfatec Pharma Gmbh Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
WO1993011231A1 (en) 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
JPH06289015A (ja) 1993-03-30 1994-10-18 Sunstar Inc フェノチアジン系色源体安定化組成物
GB9316727D0 (en) 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
GB9317193D0 (en) 1993-08-18 1993-10-06 Zeneca Ltd Method
WO1996004915A1 (en) 1994-08-08 1996-02-22 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
DE4430091A1 (de) 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
US5693638A (en) 1996-02-23 1997-12-02 Myers; Daniel Method of treating a migraine headache
US6333322B1 (en) 1996-03-13 2001-12-25 Eisai Co., Ltd. Nitrogen-containing tricyclic compounds and drugs containing the same
WO1998031219A1 (en) 1997-01-21 1998-07-23 The American National Red Cross Intracellular and extracellular decontamination of whole blood and blood components by amphiphilic phenothiazin-5-ium dyes plus light
WO1999062548A1 (en) 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies
FR2788436A1 (fr) 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
WO2001053340A2 (en) 2000-01-21 2001-07-26 Pharmacia & Upjohn Company Transgenic mouse model of human neurodegenerative disease
GB0017060D0 (en) 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US20020197258A1 (en) 2001-06-22 2002-12-26 Ghanbari Hossein A. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US7410965B2 (en) 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
US6953974B2 (en) * 2003-08-26 2005-10-11 Texas Instruments Incorporated EEPROM device and method for providing lower programming voltage
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
BRPI0416928A (pt) 2003-11-28 2007-01-16 Photopharmica Ltd desenvolvimento de derivados biologicamente ativos de azul de metileno
WO2006032879A2 (en) 2004-09-23 2006-03-30 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
JP5186212B2 (ja) 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
US20070116757A1 (en) 2005-11-08 2007-05-24 Collegium Pharmaceutical, Inc. Methylene Blue Derivatives
DK2004155T3 (en) 2006-03-29 2018-04-30 Wista Lab Ltd PROTEIN AGGREGATION INHIBITORS
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
DK2853293T3 (en) 2006-03-29 2018-01-22 Wista Lab Ltd Thioninium compounds and their use
MY162313A (en) 2006-07-11 2017-05-31 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
AU2008265045B2 (en) 2007-06-19 2014-02-27 Taurx Therapeutics Management Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
PT2954932T (pt) 2007-10-03 2018-12-12 Wista Lab Ltd Utilização terapêutica de diaminofenotiazinas
KR101888713B1 (ko) 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
JP7317787B2 (ja) 2020-10-19 2023-07-31 トヨタ自動車株式会社 排ガス浄化装置

Also Published As

Publication number Publication date
CN104606199B (zh) 2022-09-13
MY143757A (en) 2011-07-15
PT2013191E (pt) 2010-10-29
US20240245700A1 (en) 2024-07-25
ATE478058T3 (de) 2010-09-15
CN104119294B (zh) 2018-10-30
US20220152038A1 (en) 2022-05-19
US20250325557A1 (en) 2025-10-23
CA2646163A1 (en) 2007-10-04
IL231890A (en) 2016-10-31
DE602007008550D1 (de) 2010-09-30
HK1209417A1 (en) 2016-04-01
HK1210047A1 (en) 2016-04-15
HK1126480A1 (en) 2009-09-04
JP2009531403A (ja) 2009-09-03
CN109384741A (zh) 2019-02-26
CN104529939B (zh) 2019-05-07
AU2007231124B2 (en) 2013-02-21
CN104606199A (zh) 2015-05-13
DK2013191T6 (en) 2019-04-23
EP2013191A2 (en) 2009-01-14
HK1199444A1 (en) 2015-07-03
CN104529939A (zh) 2015-04-22
WO2007110627A3 (en) 2007-11-22
IL194516A0 (en) 2009-08-03
JP2014055165A (ja) 2014-03-27
PL2013191T3 (pl) 2011-02-28
US20090054419A1 (en) 2009-02-26
US12324810B2 (en) 2025-06-10
ES2349322T3 (es) 2010-12-29
KR100983301B1 (ko) 2010-09-20
CN109384741B (zh) 2023-01-06
ES2349322T7 (es) 2019-10-17
US7888350B2 (en) 2011-02-15
EA014552B1 (ru) 2010-12-30
JP5520043B2 (ja) 2014-06-11
PL2013191T6 (pl) 2019-07-31
CN101460472B (zh) 2015-06-17
IL194516A (en) 2015-02-26
AU2007231124A1 (en) 2007-10-04
KR20080110879A (ko) 2008-12-19
US11951110B2 (en) 2024-04-09
US20160051559A1 (en) 2016-02-25
DK2013191T3 (da) 2010-11-22
HRP20100614T1 (hr) 2010-12-31
EA200870384A1 (ru) 2009-04-28
EP2013191B3 (en) 2019-02-27
JP5814957B2 (ja) 2015-11-17
CN104119294A (zh) 2014-10-29
IL231890A0 (en) 2014-05-28
WO2007110627A2 (en) 2007-10-04
US11344558B2 (en) 2022-05-31
CA2646163C (en) 2011-03-15
JP2013121985A (ja) 2013-06-20
CA2646163F (en) 2007-10-04
CN101460472A (zh) 2009-06-17
EP2013191B1 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
CA2646163A1 (en) 3,7-diamino-10h-phenothiazine salts and their use
EA200401194A1 (ru) Миметики глюкокортикоидов, способы их получения, фармацевтические композиции и их применение
AR052948A1 (es) DERIVADOS DE ACETILENIL-PIRAZOLO-PIRIMIDINA COMO ANTAGONISTAS DE MGLUR2, METODOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU EMPLEO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES DEL SNC
DK155977B (da) Fremgangsmaade til fremstilling af en stabil injicerbar vandig oploesning af et tetracyclin-antibiotikum og en jordalkalimetalforbindelse
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados
EA202192512A1 (ru) Пиримидоновые производные с конденсированными кольцами для применения в лечении инфекции, вызванной hbv, или заболеваний, вызванных hbv
DK1427708T3 (da) Amino-phthalazinon-derivater som kinase-inhibitorer, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger der indeholder det samme
JP2009531403A5 (enExample)
ATE403648T1 (de) Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung
AR037182A1 (es) Compuestos del acido 4,5-disubstituido-n-acilpirrolidina-2-carboxilico, formulacion farmaceutica que lo comprende, uso del mismo para preparar un medicamento y proceso para su fabricacion
EA201992771A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
EP2581376A4 (en) MATRIC ACID / MATRIN DERIVATIVES AND MANUFACTURING METHOD AND USES THEREOF
HRP20050830A2 (en) Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases
WO2024259233A3 (en) Fused bicyclic heterocyclic or hetero aryl amide compounds
ECSP045469A (es) El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas
MA54200B1 (fr) Procédé industriel pour la préparation d'estétrol de pureté élevée
PE20240691A1 (es) Compuestos moduladores de gcn2 y usos de los mismos
CO2023002940A2 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
EA202192760A1 (ru) Трициклические соединения
ES2111700T3 (es) Derivados de cis-epoxidos, utilizables como inhibidores irreversibles de la proteasa de hiv, y procedimientos e intermediarios para su preparacion.
CA2534003A1 (en) 3-quinuclidinyl-n-biarylamides as nicotinic acetylcholine receptor agonists
ATE445589T1 (de) Neue retinoidderivate und eine pharmazeutische anti-krebs-zusammensetzung, die diese verbindungen enthält
BRPI0607214A2 (pt) derivados de 2-(4-cianofenilamino) pirimidina inibidores de hiv
AR037261A1 (es) Amidas de acido antranilico, un proceso para su preparacion, composiciones farmaceuticas, y el uso de dichas amidas para la preaparacion de un medicamento